Attopsemi Technology Co., LTD – Trademark Portfolio
Entity Type: 99
Attopsemi Technology Co., LTD holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include ATTOPSEMI and I-FUSE S³. The owner is based in Hsinchu.
15F-1, No. 118, Ciyun Road, East Dist.
Hsinchu 30072 , TW
Showing of trademarks Trademarks
Trademark Classifications
Attopsemi Technology Co., LTD's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Attopsemi Technology Co., LTD have?
Attopsemi Technology Co., LTD has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 1 cancelled.
What trademark classes does Attopsemi Technology Co., LTD file in?
Attopsemi Technology Co., LTD files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Attopsemi Technology Co., LTD's most well-known trademarks?
Attopsemi Technology Co., LTD's registered trademark portfolio includes well-known marks such as ATTOPSEMI and I-FUSE S³. These are among 2 currently registered trademarks in the portfolio.
What is Attopsemi Technology Co., LTD's trademark registration success rate?
Attopsemi Technology Co., LTD has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 1 application is pending review.